Literature DB >> 23195429

Caveolin-1 deficiency induces spontaneous endothelial-to-mesenchymal transition in murine pulmonary endothelial cells in vitro.

Zhaodong Li1, Peter J Wermuth, Bryan S Benn, Michael P Lisanti, Sergio A Jimenez.   

Abstract

It was previously demonstrated that transforming growth factor β (TGF-β) induces endothelial-to-mesenchymal transition (EndoMT) in murine lung endothelial cells (ECs) in vitro. Owing to the important role of caveolin-1 (CAV1) in TGF-β receptor internalization and TGF-β signaling, the participation of CAV1 in the induction of EndoMT in murine lung ECs was investigated. Pulmonary ECs were isolated from wild-type and Cav1 knockout mice using immunomagnetic methods with sequential anti-CD31 and anti-CD102 antibody selection followed by in vitro culture and treatment with TGF-β1. EndoMT was assessed by semiquantitative RT-PCR for Acta2, Col1a1, Snai1, and Snai2; by immunofluorescence for α-smooth muscle actin; and by Western blot analysis for α-smooth muscle actin, SNAIL1, SNAIL2, and the α2 chain of type I collagen. The same studies were performed in Cav1(-/-) pulmonary ECs after restoration of functional CAV1 domains using a cell-permeable CAV1 scaffolding domain peptide. Pulmonary ECs from Cav1 knockout mice displayed high levels of spontaneous Acta2, Col1A, Snai1, and Snai2 expression, which increased after TGF-β treatment. Spontaneous and TGF-β1-stimulated EndoMT were abrogated by the restoration of functional CAV1 domains using a cell-permeable peptide. The findings suggest that CAV1 regulation of EndoMT may play a role in the development of fibroproliferative vasculopathies.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23195429      PMCID: PMC3562733          DOI: 10.1016/j.ajpath.2012.10.022

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

Review 1.  New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies.

Authors:  Mitchell A Watsky; Karl T Weber; Yao Sun; Arnold Postlethwaite
Journal:  Int Rev Cell Mol Biol       Date:  2010-06-18       Impact factor: 6.813

2.  Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.

Authors:  Jean-François Jasmin; Isabelle Mercier; Jocelyn Dupuis; Herbert B Tanowitz; Michael P Lisanti
Journal:  Circulation       Date:  2006-08-29       Impact factor: 29.690

Review 3.  Myofibroblast differentiation and survival in fibrotic disease.

Authors:  Kornelia Kis; Xiaoqiu Liu; James S Hagood
Journal:  Expert Rev Mol Med       Date:  2011-08-23       Impact factor: 5.600

4.  A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro.

Authors:  A Schlegel; R B Schwab; P E Scherer; M P Lisanti
Journal:  J Biol Chem       Date:  1999-08-06       Impact factor: 5.157

5.  Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development.

Authors:  Enrique Arciniegas; Carmen Yudith Neves; Luz Marina Carrillo; Edgar A Zambrano; Richard Ramírez
Journal:  Endothelium       Date:  2005 Jul-Aug

6.  A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition.

Authors:  Theresa Vincent; Etienne P A Neve; Jill R Johnson; Alexander Kukalev; Federico Rojo; Joan Albanell; Kristian Pietras; Ismo Virtanen; Lennart Philipson; Philip L Leopold; Ronald G Crystal; Antonio Garcia de Herreros; Aristidis Moustakas; Ralf F Pettersson; Jonas Fuxe
Journal:  Nat Cell Biol       Date:  2009-07-13       Impact factor: 28.824

7.  Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo.

Authors:  Elena Tourkina; Mathieu Richard; Pal Gööz; Michael Bonner; Jaspreet Pannu; Russell Harley; Pascal N Bernatchez; William C Sessa; Richard M Silver; Stanley Hoffman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-01-18       Impact factor: 5.464

8.  Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.

Authors:  Francesco Del Galdo; Federica Sotgia; Cecilia J de Almeida; Jean-Francois Jasmin; Megan Musick; Michael P Lisanti; Sergio A Jiménez
Journal:  Arthritis Rheum       Date:  2008-09

9.  Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis.

Authors:  Xiao Mei Wang; Yingze Zhang; Hong Pyo Kim; Zhihong Zhou; Carol A Feghali-Bostwick; Fang Liu; Emeka Ifedigbo; Xiaohui Xu; Tim D Oury; Naftali Kaminski; Augustine M K Choi
Journal:  J Exp Med       Date:  2006-12-18       Impact factor: 14.307

Review 10.  Cancer associated fibroblasts (CAFs) in tumor microenvironment.

Authors:  Fei Xing; Jamila Saidou; Kounosuke Watabe
Journal:  Front Biosci (Landmark Ed)       Date:  2010-01-01
View more
  23 in total

1.  Inflammation-induced caveolin-1 and BMPRII depletion promotes endothelial dysfunction and TGF-β-driven pulmonary vascular remodeling.

Authors:  Suellen D S Oliveira; Maricela Castellon; Jiwang Chen; Marcelo G Bonini; Xiaowu Gu; Michael H Elliott; Roberto F Machado; Richard D Minshall
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-02-10       Impact factor: 5.464

Review 2.  Endothelial dysfunction: the role of sterol regulatory element-binding protein-induced NOD-like receptor family pyrin domain-containing protein 3 inflammasome in atherosclerosis.

Authors:  Zhen Chen; Marcy Martin; Zhao Li; John Y-J Shyy
Journal:  Curr Opin Lipidol       Date:  2014-10       Impact factor: 4.776

Review 3.  Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Physiol Rev       Date:  2019-04-01       Impact factor: 37.312

4.  Loss of caveolin-1 causes blood-retinal barrier breakdown, venous enlargement, and mural cell alteration.

Authors:  Xiaowu Gu; Steven J Fliesler; You-Yang Zhao; William B Stallcup; Alex W Cohen; Michael H Elliott
Journal:  Am J Pathol       Date:  2013-12-08       Impact factor: 4.307

Review 5.  Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?

Authors:  Sergio A Jimenez; Sonsoles Piera-Velazquez
Journal:  Matrix Biol       Date:  2016-01-22       Impact factor: 11.583

6.  Injury-Induced Shedding of Extracellular Vesicles Depletes Endothelial Cells of Cav-1 (Caveolin-1) and Enables TGF-β (Transforming Growth Factor-β)-Dependent Pulmonary Arterial Hypertension.

Authors:  Suellen D S Oliveira; Jiwang Chen; Maricela Castellon; Mao Mao; J Usha Raj; Suzy Comhair; Serpil Erzurum; Claudia L M Silva; Roberto F Machado; Marcelo G Bonini; Richard D Minshall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06       Impact factor: 8.311

7.  To be EndMT or not to be, that is the question in pulmonary hypertension.

Authors:  Jianhua Xiong
Journal:  Protein Cell       Date:  2015-08       Impact factor: 14.870

Review 8.  Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.

Authors:  Sergio A Jimenez
Journal:  ISRN Rheumatol       Date:  2013-09-23

9.  Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial-mesenchymal transition and fibrosis during peritoneal dialysis.

Authors:  Raffaele Strippoli; Jesús Loureiro; Vanessa Moreno; Ignacio Benedicto; María Luisa Pérez Lozano; Olga Barreiro; Teijo Pellinen; Susana Minguet; Miguel Foronda; Maria Teresa Osteso; Enrique Calvo; Jesús Vázquez; Manuel López Cabrera; Miguel Angel del Pozo
Journal:  EMBO Mol Med       Date:  2015-01       Impact factor: 12.137

Review 10.  Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis.

Authors:  Manuel López-Cabrera
Journal:  Adv Med       Date:  2014-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.